Business Wire

CHRYSO®Quad: A Range of Admixtures and Services for Complex Local Sands and Aggregates, in Support of the Circular Economy

Share

To support sustainable construction stakeholders, CHRYSO is strengthening its CHRYSO®Quad range and associated services in response to the challenges of the circular economy. CHRYSO promotes the use of complex aggregates sourced locally or from recycled concrete from deconstruction sites.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005807/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CHRYSO®Quad fosters local sourcing of aggregates and sands (Photo: Shutterstock)

Dedicated services to characterize materials and adjust admixture solutions

It all starts with the analysis of sands using the patented CHRYSO®CLEAR Test method, which diagnoses the presence of swelling clay. Then, the dedicated CHRYSO®Quad Lab service allows CHRYSO experts to carry out a precise diagnosis of a series of additional parameters: particle size (to determine the lack or excess of fines), absorption, shape factors, etc.

Additionally, compaction tests are performed in CHRYSO's application laboratories to consider all the parameters of the concrete mix design. Finally, the brand-new digitalized service CHRYSO®Quad App proposes the most suitable admixture solution based on the customer's material characterization (sands and aggregates) and thus broadens the scope of potential supply sources.

The use of complex aggregates and sands while improving concrete performance

The customized CHRYSO®Quad admixture solutions are adjusted according to the available resources of complex sands and aggregates. This allows clients to gain flexibility by integrating new sands and aggregates into their concrete mix and overcome shortages or tensions in material supplies. CHRYSO experts accompany their clients in producing durable and robust concrete that can withstand material variations.

CHRYSO®Quad contributes to the circular economy and reduces the carbon footprint

By anticipating the constraints of quality and availability of local sands and aggregates, CHRYSO®Quad fully embraces a circular economy approach.

CHRYSO®Quad is a development lever for recycling materials from deconstruction, allowing for the recovery and use of recycled aggregates.

The use of local resources also contributes to reducing supply costs and decreasing the carbon footprint associated with the transportation of raw materials.

CHRYSO continues to deploy CHRYSO®Quad

To date, 9 million m3 of concrete have already benefited from CHRYSO®Quad solutions, including on large construction sites around the world. Leveraging its international network of application laboratories, CHRYSO provides answers to the sourcing challenges of aggregates faced by industry stakeholders.

CASE STUDY

With CHRYSO®Quad 870, a concrete industry player manages to use 100% of complex sands in its concrete formulation

To support a client in the south of France in optimizing the sand resources used in its concrete formulation, CHRYSO proposed its CHRYSO®Quad 870 solution, which improved productivity, concrete quality, and allowed for sourcing exclusively from local suppliers.

This industry player supplied his plant with sand from two quarries. A complex crushed sand, sourced from a quarry near the plant. A second "corrective" sand, from another quarry located 60km from the plant. Up to 50% of each sand was used in the different concrete mixes, which ranged from class S3 to S5.

In its specifications, the industry player requested that CHRYSO provides a solution to increase its capacity to use complex sands (with a high content of fines and the presence of clays). Thanks to the CHRYSO®Quad Lab service, sands were recovered and analyzed in the laboratory and in the plants. This allowed CHRYSO to design the customized CHRYSO®Quad 870 product. The first product testing phases were validated on site by sand variability checks carried out by the client using the CHRYSO®CLEAR Test kit.

As a result, the customer has extended the use of CHRYSO®Quad 870 to three other concrete plants and now uses 100% complex sand from a local quarry. The use of a single sand, with a constant dosage, brings a benefit of regularity in the production, reducing the weight of CEM II A cement in the design mix, which represents a 10% reduction of the carbon footprint. In addition, thanks to the exclusive use of short-distance sourcing, 24 lorry journeys per month have been avoided.

ABOUT SAINT-GOBAIN CONSTRUCTION CHEMICALS

Saint-Gobain Construction Chemicals offers cement additives, concrete admixtures and specialty building materials, through the combined activities of Chryso and GCP. Its recent technologies for sustainable construction help reduce energy consumption, lower the carbon footprint of cements and concrete, and foster the circular economy. Leveraging its global manufacturing presence, Saint-Gobain Construction Chemicals serves its customers through local sites in over 40 countries, employing over 2,700 people.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press relations
CHRYSO
Daphnée DECAUDIN
Daphnee.decaudin@chryso.com
+33 6 19 07 64 74

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye